Alnylam Pharmaceuticals, Inc (ALNY)

Alnylam Pharmaceuticals' stock price experienced fluctuations between November 2025 and May 2026. The stock closed at $451.23 in November 2025 and reached a high of $397.65 in December 2025, before closing at $295.05 in May 2026. In February 2026, Alnylam reported strong fourth quarter and full-year 2025 financial results, achieving global net product revenues of nearly $3 billion, an 81% increase year-over-year, and reaching profitability, driven by increased demand for AMVUTTRA. In April 2026, the company announced its Q1 2026 earnings, reporting $1.99 EPS and revenue of $1.17 billion, up approximately 96% year-over-year; however, the stock price dipped due to investors focusing on reiterated full-year 2026 net product revenue guidance. The 52-week high for ALNY stock was $495.55, and the 52-week low was $252.79.

No specific information regarding demand seasonality for Alnylam Pharmaceuticals' products and services was found in the provided search results. General stock seasonality charts do not indicate specific seasonal patterns for the demand of Alnylam's pharmaceutical products.

Alnylam Pharmaceuticals is a biopharmaceutical company focused on RNAi therapeutics, utilizing gene silencing to treat diseases. Their strategy targets genetically validated genes associated with human diseases, using delivery methods like GalNAc conjugates or LNPs to deliver siRNAs, primarily to the liver. Alnylam's marketed products include AMVUTTRA for hATTR with polyneuropathy and ATTR cardiomyopathy, ONPATTRO for the polyneuropathy of hATTR amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio (developed and commercialized by Novartis AG) for hypercholesterolemia or mixed dyslipidemia. Alnylam has a pipeline of investigational RNAi therapeutics focused on Genetic Medicines, Cardio-Metabolic Diseases, Infectious Disease, and CNS/Ocular Diseases.

Alnylam Pharmaceuticals has a significant global presence with its headquarters and research labs in Cambridge, Massachusetts, and manufacturing facilities in Cambridge and Norton, Massachusetts. In Europe, it has business offices in Maidenhead, UK, and Zug, Switzerland, with satellite offices in Munich, Germany; Amsterdam, Netherlands; Vienna, Austria; Paris, France; Milan, Italy; Madrid, Spain; and Stockholm, Sweden. Other global offices include Tokyo, Japan; Sao Paulo, Brazil; and Mississauga, Ontario, Canada. Alnylam employs over 2,000 people worldwide and has additional offices in 20 other countries.

Alnylam Pharmaceuticals has a strong brand reputation as a leader in RNAi therapeutics, recognized for its innovative approach to developing therapies for genetically defined diseases. Alnylam was included on Forbes' "100 Most Innovative Growth Companies" list in 2016. More recently, Alnylam was named one of Fast Company's Most Innovative Companies for 2026 and recognized by Newsweek as one of America's Most Responsible Companies. The company is executing its "Alnylam 2030" strategy, focused on accelerating innovation and scaling its impact to transform human health. There is no information available regarding events that negatively affected Alnylam's reputation in the past year.

Alnylam Pharmaceuticals, Inc. has a predominantly institutional ownership structure. As of May 7, 2026, there were 851 institutional owners and shareholders holding a total of 130,548,000 shares. Major institutional owners include Capital World Investors, Fmr Llc, Vanguard Group Inc, BlackRock, Inc., Capital Research Global Investors, JPMorgan Chase & Co, State Street Corp, Geode Capital Management, Llc, Baillie Gifford & Co, and Pacer Advisors, Inc. Institutional investors hold 96.37% of the company, while individual ownership is 0.26%. Insider stakes are generally low.